PMGC Holdings Inc. (ELAB)
NASDAQ: ELAB · Real-Time Price · USD
4.420
-0.360 (-7.53%)
At close: Sep 21, 2026, 4:00 PM EDT
4.410
-0.010 (-0.23%)
After-hours: Sep 21, 2026, 5:57 PM EDT
PMGC Holdings Revenue
PMGC Holdings had revenue of $1.31M in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $2.58M. In the year 2025, PMGC Holdings had annual revenue of $590.08K.
Revenue (ttm)
$2.58M
Revenue Growth
n/a
P/S Ratio
1.40
Revenue / Employee
$75,844
Employees
34
Market Cap
3.58M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 590.08K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 766.28K | 765.45K | 92,557.44% |
| Dec 31, 2021 | 827.00 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| HCW Biologics | 6.72M |
| 60 Degrees Pharmaceuticals | 1.21M |
| GeoVax Labs | 852.28K |
| BioRestorative Therapies | 357.87K |
| Addex Therapeutics | 136.51K |
| VivoSim Labs | 112.00K |
| Jupiter Neurosciences | 64.69K |
| Alaunos Therapeutics | 3.00K |
ELAB News
- 3 days ago - PMGC secures 5-year royalty stream from Elevai Skincare sale - TheFly
- 3 days ago - PMGC Holdings Inc. (Nasdaq: ELAB) Secures Five-Year Royalty Stream from Elevai Skincare Sale Under Executed Payment Agreement with Longevity Health Holdings - GlobeNewsWire
- 20 days ago - NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications - GlobeNewsWire
- 26 days ago - PMGC terminates non-binding letter of intent to acquire Arizona company - TheFly
- 26 days ago - PMGC Holdings Terminates Previously Announced Acquisition LOI Following Due Diligence Review; Reaffirms Disciplined M&A Strategy and Expands Investment Across Aerospace & Defense Manufacturing Portfolio - GlobeNewsWire
- 27 days ago - PMGC announces term sheet with Orbit2Orbit - TheFly
- 27 days ago - PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22 and EL-32, Targeting Microgravity-Induced Muscle Loss - GlobeNewsWire
- 4 weeks ago - NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight - GlobeNewsWire